Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
Psoriasis and Psoriatic Arthritis Drugs Crisscross Categories, but Derm and Rheum Docs Split on Preferences
As drugs in psoriasis and psoriatic arthritis therapy areas nab new indications that crisscross the two categories, dermatologists and rheumatologists are assessing their options. The twist? Emerging opinions between the two doctor groups are exactly the opposite, according to Spherix Global Insights research analysis.
Hidradenitis Suppurativa — The Future of Patient Management
![](https://www.spherixglobalinsights.com/wp-content/uploads/2020/12/spherix-global-insights-default-og.png)
Spherix’s Dermatology Franchise Head, Gianna Melendez, discusses insights she’s uncovered from her work in the hidradenitis suppurativa (HS) market and looks to the future of disease management. What is hidradenitis suppurativa? Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory condition that causes painful and recurrent abscesses. Eventually, the illness progresses to the […]
Incyte’s eczema cream Opzelura off to ‘very successful’ launch despite FDA warning: CEO
When Incyte’s Jakafi sister med Opzelura entered the atopic dermatitis market with unexpected FDA safety warnings, industry watchers worried doctors would balk at prescribing the cream. But early results suggest that’s not the case, and one analyst figures the drug could double the Street’s 2022 sales expectations…
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, Rheumatology, Ophthalmology, Nephrology, and Neurology Markets Highlighted in New Spherix Study
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., December 8, 2021 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
Unmet Need for New Treatment Options and Barriers to Adalimumab Use in Hidradenitis Suppurativa
Author: Gianna Melendez INTRODUCTION: Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory condition that presents as painful and recurrent abscesses that progress to sinus tracts and scarring in the intertriginous locations of the body, causing low quality of life in most patients. HS often develops when hair follicles become blocked and is […]
Uptake of Baricitinib For The Treatment of Moderate-To-Severe Atopic Dermatitis in Germany
Author: Gianna Melendez INTRODUCTION: Since 2017, dupilumab has been the only advanced systemic option for patients with moderate-to-severe atopic dermatitis (AD), leaving a large unmet need for new treatments. Though widely perceived as efficacious and safe, most EU5 dermatologists agree that the biologic does not work well in all moderate-to-severe AD patients. In October […]
‘Erratic’ FDA and Inconsistent Drug Decisions Put Doctors Off New Meds: Survey
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately—and doctors have had enough. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in […]
Specialty Physicians Weigh in with Opinions About the US Food and Drug Administration
![](https://www.spherixglobalinsights.com/wp-content/uploads/2020/12/spherix-logo-400x400-1.png)
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat, Ardelyx’s tenapanor, and the entire JAK inhibitor class EXTON, Pa., July 27, 2021 /PRNewswire/ — In reaction to major market events over the past several months, analysts at Spherix recently captured an increasingly negative sentiment towards the […]
New Spherix Global Insights’ Patient Audit Highlights Key Differences Between Dermatologists’ and Rheumatologists’ Management of Psoriatic Arthritis, Focusing on Patients Recently Switched Between Advanced Systemic Treatment Brands
US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different drivers behind key treatment decisions in patient management EXTON, Pa., April 28, 2021 /PRNewswire/ – The past five or so years have seen a flurry of US biologic approvals for the treatment of psoriasis (PSO), […]